vs
ROYAL GOLD INC（RGLD）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是ROYAL GOLD INC的1.7倍（$622.0M vs $375.3M），Royalty Pharma plc净利率更高（34.4% vs 24.9%，领先9.5%），ROYAL GOLD INC同比增速更快（85.3% vs 4.8%），过去两年ROYAL GOLD INC的营收复合增速更高（58.8% vs 4.6%）
Royal Gold Inc.是全球领先的贵金属流权与特许权经营企业，收购并管理多元化的矿业项目流权、净熔炼收益特许权及相关权益，资产覆盖黄金、白银、铜等品类，业务遍及多地区，无需直接承担采矿运营风险。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
RGLD vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.7倍
$375.3M
营收增速更快
RGLD
高出80.5%
4.8%
净利率更高
RPRX
高出9.5%
24.9%
两年增速更快
RGLD
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $375.3M | $622.0M |
| 净利润 | $93.6M | $214.2M |
| 毛利率 | 64.6% | — |
| 营业利润率 | 56.2% | 62.4% |
| 净利率 | 24.9% | 34.4% |
| 营收同比 | 85.3% | 4.8% |
| 净利润同比 | -12.8% | 2.9% |
| 每股收益（稀释后） | $1.04 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RGLDRPRX
| Q4 25 | $375.3M | $622.0M | ||
| Q3 25 | $252.1M | $609.3M | ||
| Q2 25 | $209.6M | $578.7M | ||
| Q1 25 | $193.4M | $568.2M | ||
| Q4 24 | $202.6M | $593.6M | ||
| Q3 24 | $193.8M | $564.7M | ||
| Q2 24 | $174.1M | $537.3M | ||
| Q1 24 | $148.9M | $568.0M |
净利润RGLDRPRX
| Q4 25 | $93.6M | $214.2M | ||
| Q3 25 | $126.8M | $288.2M | ||
| Q2 25 | $132.3M | $30.2M | ||
| Q1 25 | $113.5M | $238.3M | ||
| Q4 24 | $107.4M | $208.2M | ||
| Q3 24 | $96.2M | $544.0M | ||
| Q2 24 | $81.2M | $102.0M | ||
| Q1 24 | $47.2M | $4.8M |
毛利率RGLDRPRX
| Q4 25 | 64.6% | — | ||
| Q3 25 | 73.6% | — | ||
| Q2 25 | 72.6% | — | ||
| Q1 25 | 69.4% | — | ||
| Q4 24 | 70.3% | — | ||
| Q3 24 | 66.6% | — | ||
| Q2 24 | 64.7% | — | ||
| Q1 24 | 58.4% | — |
营业利润率RGLDRPRX
| Q4 25 | 56.2% | 62.4% | ||
| Q3 25 | 64.4% | 70.1% | ||
| Q2 25 | 67.7% | 36.3% | ||
| Q1 25 | 63.6% | 94.0% | ||
| Q4 24 | 65.9% | 60.9% | ||
| Q3 24 | 61.3% | — | ||
| Q2 24 | 58.6% | 50.2% | ||
| Q1 24 | 50.7% | -13.0% |
净利率RGLDRPRX
| Q4 25 | 24.9% | 34.4% | ||
| Q3 25 | 50.3% | 47.3% | ||
| Q2 25 | 63.1% | 5.2% | ||
| Q1 25 | 58.7% | 41.9% | ||
| Q4 24 | 53.0% | 35.1% | ||
| Q3 24 | 49.7% | 96.3% | ||
| Q2 24 | 46.6% | 19.0% | ||
| Q1 24 | 31.7% | 0.8% |
每股收益（稀释后）RGLDRPRX
| Q4 25 | $1.04 | $0.49 | ||
| Q3 25 | $1.92 | $0.67 | ||
| Q2 25 | $2.01 | $0.07 | ||
| Q1 25 | $1.72 | $0.55 | ||
| Q4 24 | $1.63 | $0.46 | ||
| Q3 24 | $1.46 | $1.21 | ||
| Q2 24 | $1.23 | $0.23 | ||
| Q1 24 | $0.72 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $233.7M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $7.2B | $9.7B |
| 总资产 | $9.5B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资RGLDRPRX
| Q4 25 | $233.7M | $618.7M | ||
| Q3 25 | $172.8M | $938.9M | ||
| Q2 25 | $248.2M | $631.9M | ||
| Q1 25 | $240.8M | $1.1B | ||
| Q4 24 | $195.5M | $929.0M | ||
| Q3 24 | $127.9M | $950.1M | ||
| Q2 24 | $74.2M | $1.8B | ||
| Q1 24 | $137.9M | $843.0M |
总债务RGLDRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | $0 | $7.6B | ||
| Q2 24 | $50.0M | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益RGLDRPRX
| Q4 25 | $7.2B | $9.7B | ||
| Q3 25 | $3.4B | $9.6B | ||
| Q2 25 | $3.3B | $9.5B | ||
| Q1 25 | $3.2B | $9.8B | ||
| Q4 24 | $3.1B | $10.3B | ||
| Q3 24 | $3.0B | $10.3B | ||
| Q2 24 | $3.0B | $9.8B | ||
| Q1 24 | $2.9B | $9.9B |
总资产RGLDRPRX
| Q4 25 | $9.5B | $19.6B | ||
| Q3 25 | $4.5B | $19.3B | ||
| Q2 25 | $3.6B | $18.3B | ||
| Q1 25 | $3.5B | $17.6B | ||
| Q4 24 | $3.4B | $18.2B | ||
| Q3 24 | $3.3B | $18.0B | ||
| Q2 24 | $3.3B | $17.7B | ||
| Q1 24 | $3.3B | $16.1B |
负债/权益比RGLDRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | 0.00× | 0.74× | ||
| Q2 24 | 0.02× | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $241.7M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 2.58× | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流RGLDRPRX
| Q4 25 | $241.7M | $827.1M | ||
| Q3 25 | $174.0M | $702.6M | ||
| Q2 25 | $152.8M | $364.0M | ||
| Q1 25 | $136.4M | $596.1M | ||
| Q4 24 | $141.1M | $742.5M | ||
| Q3 24 | $136.7M | $703.6M | ||
| Q2 24 | $113.5M | $658.2M | ||
| Q1 24 | $138.3M | $664.6M |
现金转化率RGLDRPRX
| Q4 25 | 2.58× | 3.86× | ||
| Q3 25 | 1.37× | 2.44× | ||
| Q2 25 | 1.15× | 12.06× | ||
| Q1 25 | 1.20× | 2.50× | ||
| Q4 24 | 1.31× | 3.57× | ||
| Q3 24 | 1.42× | 1.29× | ||
| Q2 24 | 1.40× | 6.45× | ||
| Q1 24 | 2.93× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RGLD
| Gold | $216.9M | 58% |
| Pueblo Viejo | $47.3M | 13% |
| Andacollo | $32.6M | 9% |
| Silver | $32.1M | 9% |
| Other | $27.2M | 7% |
| Copper | $13.7M | 4% |
| Cortez Legacy Zone | $5.4M | 1% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
